Development of Transdermal Drug Delivery Approaches to Combat Diabetes: An Update.

In recent years, transdermal drug delivery systems (TDDS) have gained popularity as a non-invasive, patient-friendly medication delivery method. This review article examines the latest transdermal medication delivery developments and breakthroughs. The review begins with a brief summary of transdermal medication administration, stressing the skin's barrier role and drug permeation methods. Novel materials and methods improve drug solubility, stability, and skin permeability in formulation technologies. A literature review of the most recent innovations in TDDS, such as nano-based delivery systems, microneedles, and smart patches, was conducted. Major challenges of drug solubility, stability, and skin permeability were carefully discussed, along with the transdermal patch designs of new therapeutic applications in pain management, cardiovascular diseases, and hormone therapy. Transdermal medication delivery difficulties may be overcome via nano-based drug delivery systems, microneedle arrays, and smart patches. Furthermore, the paper discusses current advances in transdermal patch design for therapeutic applications, highlighting effective instances in pain management, cardiovascular illness, and hormone therapy. The article examines transdermal medication delivery regulations, safety, and patient compliance in addition to technological advances. The complete study in this review seeks to help academics, doctors, and pharmaceutical professionals understand transdermal drug delivery and its future. Understanding recent advances in this field can help stakeholders design more effective and patient-friendly transdermal drug delivery systems, enhancing treatment outcomes and patient well-being.

In vivo real-time monitoring system of electroporation mediated control of transdermal and topical drug delivery

Background: Transdermal delivery has become a crucial field in pharmaceutical research. There has been a proliferation of innovative methods for transdermal drug delivery. In recent years, the number of publications regarding transdermal drug delivery has been rising rapidly. To investigate the current research trends and hotspots in transdermal drug delivery, a comprehensive bibliometric analysis was performed. Methods: An extensive literature review was conducted to gather information on transdermal drug delivery that had been published between 2003 and 2022. The articles were obtained from the Web of Science (WOS) and the National Center for Biotechnology Information (NCBI) databases. Subsequently, the collected data underwent analysis and visualization using a variety of software tools. This approach enables a deeper exploration of the hotspots and emerging trends within this particular research domain. Results: The results showed that the number of articles published on transdermal delivery has increased steadily over the years, with a total of 2,555 articles being analyzed. The most frequently cited articles were related to the optimization of drug delivery and the use of nanotechnology in transdermal drug delivery. The most active countries in the field of transdermal delivery research were the China, United States, and India. Furthermore, the hotspots over the past 2decades were identified (e.g., drug therapy, drug delivery, and pharmaceutical preparations and drug design). The shift in research focus reflects an increasing emphasis on drug delivery and control release, rather than simply absorption and penetration, and suggests a growing interest in engineering approaches to transdermal drug delivery. Conclusion: This study provided a comprehensive overview of transdermal delivery research. The research indicated that transdermal delivery would be a rapidly evolving field with many opportunities for future research and development. Moreover, this bibliometric analysis will help researchers gain insights into transdermal drug delivery research's hotspots and trends accurately and quickly.

Drugs have been applied to the skin to treat superficial disorders and for cosmetic purposes since ancient times. Although early records suggest that the skin has also been used as a portal of entry for the systemic delivery of drugs, it was not until the latter third of the 20th century that transdermal delivery, particularly through the use of transdermal patches, became a common practice. Today, nearly 20 drugs have been successfully incorporated into transdermal drug delivery systems (TDDS) and delivered through the skin to treat general illnesses. The limited number of drugs available on the market when compared to conventional dosage forms (e.g. oral and intravenous products) can be mainly explained by the remarkable barrier property of the skin. This results in the selection of chemical candidates possessing adequate physicochemical properties to penetrate into and permeate through the skin. Moreover, therapeutically relevant levels of the candidate chemical need to reach the target site and TDDS have to demonstrate an unmet clinical need compared to already available dosage forms in terms of safety, patient compliance, and cost. This chapter first gives a perspective history of TDDS and their advantages and limitations. The three main requirements that a chemical candidate must possess in order to be successfully delivered using TDDS are then presented. Finally, the future prospects for TDDS for the management of general conditions are discussed.

Nanoconstructs, such as liposomes, polymeric micelles, gold nanoparticles, carbon nanomaterials and nanocrystalline quantum dots, have been widely investigated for diagnostic, bioimaging and therapeutic applications [1]. Nanoconstructs have been also extensively explored in the field of dermatology. For example, liposomes and polymeric nanoparticles loaded with drugs were applied as topical administration agents for the treatment of skin diseases such as psoriasis, dermatitis and skin cancer [2,3]. Titanium dioxide and zinc oxide (ZnO) nanoparticles have been used as sun-screen formulation for the protection of skin from UV by the scattering, absorption and reflection of UV [4]. Silver nanoparticles are commercially used as wound and burn dressing agents with antibacterial effects [5]. Quantum dots and ZnO nanoparticles were utilized as bioimaging agents for the diagnosis of skin diseases [6,7]. Moreover, gold nanoconstructs and carbon nanomaterials have been actively investigated as promising agents for the photothermal ablation therapy of skin cancers due to their high light-to-heat conversion capability [8,9]. For further applications of nanoconstructs in dermatology, we need efficient transdermal delivery carriers of the nanoconstructs. The transdermal delivery has several advantages over other administration routes, such as oral delivery and needle based injection. The advantages include noninvasive treatment, self-administration, improved patient compliance and avoidance of hepatic first-pass metabolism or digestion system [10]. Despite these benefits, the low skin permeability of nanoconstructs such as polymers, proteins, hydrophilic drugs and nanoparticles limited their wide applications to the transdermal delivery. To facilitate the transdermal delivery of nanoconstructs, additional treatments have been adopted using penetration enhancers, iontophoresis, ultrasound and microneedles [11]. However, these methods require physical perturbations to the skin tissue, causing skin damage in some cases [12]. A noninvasive molecular carrier for transdermal delivery would have compelling advantages. The understanding for the characteristics of skin layers can be a good starting point for the development of transdermal delivery carriers of nanoconstructs. Stratum corneum (SC), the outermost skin layer, is the main barrier composed of densely packed dead cells forming hydrophobic surfaces. For the penetration of hydrophobic SC, hydrophobic molecules have clear benefits over hydrophilic molecules. The hydrophobic molecules can infiltrate into densely packed lipid layers in SC. However, nanoconstructs are usually formulated to have hydrophilic surfaces enhancing the physiological stability in the biological conditions. This contradicting requirement of hydrophobicity and hydrophilicity for transdermal delivery should be reconciled to enhance the physiological stability and the skin permeability by lipid disruption in SC. Recently, hyaluronic acid (HA) has been investigated as a promising transdermal delivery carrier. HA is a naturally occurring linear polysaccharide composed of repeating units of d-glucuronic acid and N-acetylEnhancing the transdermal penetration of nanoconstructs: could hyaluronic acid be the key?

Nanotechnology, for the past few years, has evolved as a new era of drug delivery for many drug systems. Transdermal drug delivery is one of the few systems which have been a major area of research these days. Transdermal Drug Delivery System (TDDS) offers many advantages as compared to traditional drug delivery systems. However TDDS has limited market success due to the barrier properties of the Stratum Corneum. Introduction of ethosomes, which are soft, malleable vesicular carriers containing ethanol tailored for enhanced delivery of active agents, has initiated a new area on vesicular research for transdermal drug delivery. Different reports show a promising future of ethosomes in making transdermal delivery of various agents more effective. Ethosomes also offer a good opportunity for the non-invasive delivery of small, medium, and large sized drug molecules. Preparation of ethosomes is easy with no complicated equipment involved and therefore can be scaled up to industrial level. This review includes introduction to ethosomes, composition and methods of preparation, evaluation and effectiveness in skin permeation. The review also highlights use of ethosomes in transdermal drug delivery in terms of quantity and depth than either liposomes or hydroalcoholic solutions. Keywords: Ethosomes, ethanol, composition, transdermal drug delivery

Transdermal drug delivery in pain management

Transdermal drug delivery systems (TDDS), also known as patches, are dosage forms designed to deliver a therapeutically effective amount of drug across a patients skin. In order to deliver therapeutic agents through the human skin for systemic effects, the comprehensive morphological, biophysical and physicochemical properties of the skin are to be considered. Transdermal delivery provides a leading edge over injectables and oral routes by increasing patient compliance and avoiding first pass metabolism respectively. Transdermal delivery not only provides controlled, constant administration of the drug, but also allows continuous input of drugs with short biological half-lives and eliminates pulsed entry into systemic circulation, which often causes undesirable side effects. The TDDS review articles provide valuable information regarding the transdermal drug delivery systems and its evaluation process details as a ready reference for the research scientist who is involved in TDDS. With the advancement in technology Pharma industries have trendified all its resources. Earlier we use convectional dosage form but now we use novel drug delivery system. One of greatest innovation of novel drug delivery is transdermal patch. The advantage of transdermal drug delivery system is that it is painless technique of administration of drugs.

Current and emerging formulation strategies for skin permeation are poised to open the transdermal drug delivery to a broader range of small molecule compounds that do not fit the traditional requirements for successful transdermal drug delivery, allowing the development of new patch technologies to deliver antiretroviral drugs that were previously incapable of being delivered through transdermal means. Transdermal drug delivery offers several distinct advantages over traditional dosage forms. Current antiretroviral drugs used for the treatment of HIV infection include a variety of highly active small molecule compounds with significantly limited skin permeability, and thus new and novel means of enhancing transport through the skin are needed. Current and emerging formulation strategies are poised to open the transdermal drug delivery to a broader range of compounds that do not fit the traditional requirements for successful transdermal drug delivery, allowing the development of new patch technologies to deliver antiretroviral drugs that were previously incapable of being delivered through transdermal means. Thus, with continuing research into skin permeability and patch formulation strategies, there is a large potential for antiretroviral transdermal drug delivery.

A complete sojourn of recent advancements and applications in transdermal drug delivery systems

3D printing applications for transdermal drug delivery

Strategies for transdermal drug delivery against bone disorders: A preclinical and clinical update

Aims:This study was performed to compare the degree of post operative analgesia, patient compliance, and frequency of adverse events with the use of oral diclofenac tablets and transdermal diclofenac patch following multiple premolar extractions in patients undergoing orthodontic treatment.Materials and Methods:Twenty young pre-orthodontic patients requiring bilateral maxillary and mandibular first premolar extractions were selected for the study. The right maxillary and mandibular first premolars were extracted first and 50 mg oral diclofenac sodium tablets were prescribed to be taken thrice a day for three days. In the next appointment, the contralateral first premolars were extracted and a 100 mg transdermal diclofenac patch was applied once a day for three days. Pain relief and pain intensity with both the diclofenac formulations was recorded for each of the three postoperative days using 5-point Verbal Pain Intensity and Pain Relief Score Charts.Results and Conclusions:Statistical analyses revealed that there was a gradual increase in pain relief scores and a gradual decrease in pain intensity scores with the use of oral diclofenac tablets as well as with the transdermal patch. However, subjects reported that they were more comfortable using the transdermal patch particularly due to the once-a-day application and lesser frequency of systemic adverse effects. Results of this study indicate that the transdermal diclofenac patch provides as potent analgesia as the oral diclofenac tablets with the added advantage of better patient compliance and may be used for routine post extraction analgesia.

Transdermal delivery of most drugs is precluded by the barrier characteristics of the stratum corneum (SC). Chemical penetration enhancers are capable of interacting with SC constituents, inducing a temporary reversible increase in the skin permeability. The aim of this work was to assess the influence of glycerol monooleate (GMO)/solvents systems on percutaneous absorption across hairless mouse SC of a lipophilic drug, progesterone (PG), as well as its effect on the SC structural characteristics, by scanning electron microscopy (SEM) and confocal laser scanning microscopy (CLSM). The morphological changes observed in the hairless mouse SC suggest a GMO effect on the skin barrier. In addition, the increase in the In vitro PG flux and in vivo penetration of a fluorescent label point towards GMO as a potential absorption enhancer. The results obtained showed that GMO/solvents systems provoked changes in the SC that could be causing increased permeation of PG across hairless mouse skin, optimising in this way the transdermal delivery of this drug.

Background: An effective substitution for conventional administration routes is transdermal medication delivery. The use of transdermal treatments to treat arthritis has increased significantly in recent years. There is a pressing need to develop a new aceclofenac transdermal medication delivery method. Objective: The current study intends to stop aceclofenac from degrading in an aqueous environment in an effort to increase the drug's stability and effectiveness when used therapeutically to treat arthritis. The goal of the current research is to create non-aqueous, hydroxypropyl methyl cellulose-based transdermal patches for aceclofenac that will improve patient compliance, increase therapeutic efficacy, decrease gastrointestinal side effects, and prevent substantial first-pass metabolism. Method: By using a solvent evaporation approach, 18 different aceclofenac transdermal patch formulations, including HPMCK4M, HPMCK100M, and HPMCK15M, were created. The characterization of these prepared transdermal patches was done in vitro. Result: DSC thermograms concluded that there is no interaction between the API and excipients. The mass, weight variation, flatness, moisture content, moisture uptake, folding endurance, thickness, medication content, and swelling tests of these transdermal patches were all assessed. Good in-vitro physicochemical qualities could be seen in all of the improved formulations. The improved transdermal Patch (P13) was chosen for in-vivo investigations based on the findings. Conclusion: In order to increase the stability and effectiveness of aceclofenac during its therapeutic use for arthritis, it can therefore be reasonably inferred that it can be made into nonaqueous transdermal matrix type patches.